Effect of donor treatment with heparinoids on graft function after intraportal transplantation of a marginal islet mass: An experimental study

Transplantation Proceedings

Volumn 36, Issue 10, 2004, Pages 3117-3120

  Juszczak, Maciej T ^a   Hughes, S J ^a   Jones, G L ^a   Powis, S H ^a   Press, M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEPARIN; HEPARINOID; ANTICOAGULANT AGENT;

ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG MEGADOSE; GLUCOSE BLOOD LEVEL; LOW DRUG DOSE; MALE; NONHUMAN; ORGAN TRANSPLANTATION; PANCREAS ISLET TRANSPLANTATION; PANCREAS RESECTION; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; STREPTOZOCIN DIABETES; ANIMAL; BLOOD; CYTOLOGY; DISEASE MODEL; EXPERIMENTAL DIABETES MELLITUS; LEWIS RAT; METABOLISM; METHODOLOGY; PANCREAS ISLET; PHYSIOLOGY; PORTAL VEIN; REFERENCE VALUE;

ANIMALS; ANTICOAGULANTS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; HEPARINOIDS; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; PORTAL VEIN; RATS; RATS, INBRED LEW; REFERENCE VALUES;

EID: 21244439963     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.10.074     Document Type: Article

References (14)

1. Lakey JR, et al: Variables in organ donors that affect the recovery of human islets of Langerhans. Transplantation 61:1047, 1996
2. Stagner JI, Samol E: Induction of angiogenesis by growth factors: relevance to pancreatic islet transplantation. EXS 61:381, 1992
3. Ishikawa Y, Kitamura M: Inhibition of glomerular cell apoptosis by heparin. Kidney Int 56:954, 1999
4. Bernfield M, et al: Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem, 68:729, 1999
5. Bennet W, et al: Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes 48:1907, 1999
6. Wang L, et al: Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 110:127, 2002
7. Frenette J, Chhinou N, Godbout C, et al: Macrophages, not neutrophils, infiltrate skeletal muscle in mice deficient in P/E selectins following mechanical reloading. Am J Physiol Regul Integr Comp Physiol 2003 285:R727, 2003
8. Matsumori A, et al: Immediate increase in circulating hepatocyte growth factor/scatter factor by heparin. J Mol Cell Cardiol 30:2145, 1998
9. Nakatani T, et al: Hepatocyte growth factor ameliorates renal hemodynamic disorder after ischemia/reperfusion. Int J Mol Med 10:217, 2002
10. Okada M, et al: Hepatocyte growth factor protects small airway epithelial cells from apoptosis induced by tumor necrosis factor-{alpha} or oxidative stress. Pediatr Res 56:336, 2004
11. Date I, et al: Hepatocyte growth factor attenuates cerebral ischemia-induced learning dysfunction. Biochem Biophys Res Commun 319:1152, 2004
12. Dai C, et al: Hepatocyte growth factor preserves beta cell mass and mitigates hyperglycemia in streptozotocin-induced diabetic mice. J Biol Chem 278:27080, 2003
13. Dzieciuchowicz L, Checinski P, Krauss H: Heparin reduces oxidative stress in the postoperative period. Med Sci Monit 8:CR657, 2002
14. Sternbergh WC III, Makhoul RG, Adelman B: Heparin prevents postischemic endothelial cell dysfunction by a mechanism independent of its anticoagulant activity. J Vasc Surg 17:318, 1993